drugset / Trial / NCT00612157

Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)

NCT00612157

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of this study is to assess the efficacy of Eszopiclone in improving short and intermediate-term compliance with continuous positive airway pressure (CPAP) in patients newly diagnosed with obstructive sleep apnea (OSA).

Timeline

Start
2008-01
Primary completion
2008-06
Completion
2009-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eszopiclone Small molecule 3 mg Oral